METTL3 and cancer: Dysregulation of m6A deposition is associated with various diseases including cancer pathogenesis and drug resistance (Huang et al., 2020; Lan et al., 2021; Zhang et al., 2021), such as the core m6A methyltransferase (METTL3) promotes the progression of breast cancer through elevating expression of mammalian hepatitis BX-interacting protein and inhibiting tumor suppressor let-7g (Cai et al., 2018), inhibits tumor immune surveillance by upregulating PD-L1 mRNA level (Wan et al., 2022), and contributes to breast cancer tamoxifen resistance by upregulation of AK4 expression (Liu et al., 2020).